In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH: None known
PREGNANCY: Pafolacianine may cause fetal harm when administered to a pregnant woman.
Obtain a pregnancy test in females of reproductive potential and verify the absence of pregnancy prior to administration of pafolacianine. Discontinue folate, folic acid, or folate containing supplements 48 hours before administration of pafolacianine. Pafolacianine is not approved for use in patients with cancer in the lung.
Please login to view the rest of this drug profile.